Organogenesis (NASDAQ:ORGO) Shares Gap Up – Time to Buy?

Organogenesis (NASDAQ:ORGO) gapped up before the market opened on Tuesday . The stock had previously closed at $4.83, but opened at $5.24. Organogenesis shares last traded at $5.0650, with a volume of 807,230 shares.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on ORGO shares. BTIG Research reissued a “buy” rating and issued a $9.00 price target on shares of Organogenesis in a report on Monday. Wall Street Zen upgraded shares of Organogenesis from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Organogenesis in a research note on Monday, December 8th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Organogenesis has a consensus rating of “Hold” and a consensus price target of $8.00.

Organogenesis Stock Performance

The company has a debt-to-equity ratio of 0.01, a current ratio of 3.32 and a quick ratio of 2.88. The firm has a market capitalization of $644.96 million, a PE ratio of -42.46 and a beta of 1.47. The company’s fifty day simple moving average is $4.77 and its 200 day simple moving average is $4.46.

Organogenesis (NASDAQ:ORGO) last posted its earnings results on Thursday, November 6th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.11. The firm had revenue of $150.86 million during the quarter, compared to the consensus estimate of $134.10 million. Organogenesis had a negative net margin of 1.30% and a positive return on equity of 4.01%. As a group, equities research analysts expect that Organogenesis will post -0.07 EPS for the current fiscal year.

Insider Transactions at Organogenesis

In other Organogenesis news, Director Glenn H. Nussdorf sold 187,957 shares of the stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $5.29, for a total transaction of $994,292.53. Following the sale, the director owned 2,765,591 shares in the company, valued at $14,629,976.39. This represents a 6.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Over the last quarter, insiders have sold 300,000 shares of company stock worth $1,592,120. Insiders own 33.00% of the company’s stock.

Institutional Trading of Organogenesis

A number of hedge funds and other institutional investors have recently made changes to their positions in ORGO. Creative Planning lifted its holdings in Organogenesis by 8.2% during the 3rd quarter. Creative Planning now owns 38,279 shares of the company’s stock worth $162,000 after purchasing an additional 2,887 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Organogenesis by 57.0% during the third quarter. BNP Paribas Financial Markets now owns 14,522 shares of the company’s stock valued at $61,000 after buying an additional 5,273 shares during the period. Quarry LP purchased a new stake in shares of Organogenesis in the third quarter worth about $25,000. State of Alaska Department of Revenue bought a new position in shares of Organogenesis in the third quarter valued at approximately $25,000. Finally, Farther Finance Advisors LLC bought a new position in shares of Organogenesis in the second quarter valued at approximately $35,000. 49.57% of the stock is currently owned by institutional investors.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.